Novartis' Kisqali off to 'very rapid' launch in early breast cancer, CEO says. Can it keep up the momentum?

31st January 2025 Uncategorised 0

One of the most important launches for Novartis in recent years is off with a bang. The question now is whether the company can sustain the momentum and propel Kisqali to $4 billion in sales in early-stage breast cancer.

More: Novartis' Kisqali off to 'very rapid' launch in early breast cancer, CEO says. Can it keep up the momentum?
Source: fierce